AUB ScholarWorks

Chronic myeloid leukemia: Archetype of the impact of targeted therapies [Leucémie myéloïde chronique: « archétype » de l'impact des traitements ciblés]

Show simple item record Nasr R. Bazarbachi A.
dc.contributor.editor Aug-2012 2017-10-05T15:41:37Z 2017-10-05T15:41:37Z 2012
dc.identifier 10.1016/j.patbio.2012.05.010
dc.identifier.issn 03698114
dc.description.abstract Chronic myeloid leukemia (CML) is a chronic blood disorder characterized by a reciprocal translocation between chromosomes 9 and 22, leading to the creation of a chimeric gene encoding the BCR-ABL fusion protein with a constitutive tyrosine kinase activity. Although long known as a disease with an inexorable progression to acute leukemia, CML history has been significantly improved by the use of imatinib, a tyrosine kinase inhibitor. Imatinib has revolutionized the treatment of CML by transforming it from an invariably fatal disease to a chronic but manageable condition. In fact, the discovery of this class of targeted therapy had an impact not only on the survival of CML patients but also on other scientific and medical fields. This review illustrates the impact of imatinib, the first example of tyrosine kinase inhibitors on the treatment of CML, on the treatment of other cancers, the impact on health systems and on the scientific research in general. © 2012 Elsevier Masson SAS.
dc.format.extent Pages: (239-245)
dc.language French
dc.publisher PARIS
dc.relation.ispartof Publication Name: Pathologie Biologie; Publication Year: 2012; Volume: 60; no. 4; Pages: (239-245);
dc.source Scopus
dc.title Chronic myeloid leukemia: Archetype of the impact of targeted therapies [Leucémie myéloïde chronique: « archétype » de l'impact des traitements ciblés]
dc.type Article
dc.contributor.affiliation Nasr, R., Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Bazarbachi, A., Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Nasr, R.; American University of Beirut, PO Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Nasr, R
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorReprintAddress Bazarbachi, A (reprint author), Amer Univ Beirut, Dept Anat Cell Biol and Physiol Sci, POB 11-0236, Beirut 11072020, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited ABELSON HT, 1970, CANCER RES, V30, P2213; ANAFI M, 1993, BLOOD, V82, P3524; [Anonymous], 1960, SCIENCE, V32, P1497; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056-NEJMoa020150; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200-JCO.2009.25.0779; Barthe C, 2001, Science, V293, P2163; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038-306277a0; Bennett J, 1845, EDINBURGH MED SURG J, V64, P413; Bonifazi F, 2001, BLOOD, V98, P3074, DOI 10.1182-blood.V98.10.3074; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182-bloo-2002-09-2896; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182-blood.V99.9.3472; Cortes JE, 2010, J CLIN ONCOL, V28, P392, DOI 10.1200-JCO.2009.25.4896; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126-science.2406902; Deininger MW, 2008, HEMATOLOGY AM SOC HE, V1, P419; Deininger MWN, 1997, BLOOD, V90, P3691; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182-blood.V101.2.690; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056-NEJMoa062867; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038-nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056-NEJM200104053441401; Faderl S, 1999, NEW ENGL J MED, V341, P164; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016-0002-9343(77)90124-3; Forkner CE, 1938, LEUKEMIA ALLIED DISO, P126; Frame David, 2007, J Manag Care Pharm, V13, P13; GALTON DAG, 1953, LANCET, V264, P208; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006-bcmd.1997.0155; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016-S0140-6736(02)08505-7; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056-NEJMra020777; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016-0092-8674(84)90077-1; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109-10428199309047857; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056-NEJM199707243370402; Hahn EA, 2003, J CLIN ONCOL, V21, P2138, DOI 10.1200-JCO.2003.12.154; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056-NEJM199804023381405; HEHLMANN R, 1994, BLOOD, V84, P4064; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038-344251a0; Huang WS, 2010, J MED CHEM, V53, P4701, DOI 10.1021-jm100395q; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056-NEJMoa030513; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038-nature07016; Jabbour E, 2007, ONCOLOGY WILLISTON P, V21; Jabbour E, 2007, ONCOLOGY WILLISTON P; Jabbour E, 2007, ONCOLOGY-NY, V21, P653; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056-NEJM200104053441404; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056-NEJMoa1002315; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056-NEJMoa011573; Kantarjian H, 2009, CANCER, V115, P4136, DOI 10.1002-cncr.24504; Keller G, 2009, EXPERT REV HEMATOL, V2, P489, DOI [10.1586-ehm.09.42, 10.1586-EHM.09.42]; Leguay T, 2005, HEMATOLOGIE, P13; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126-science.2408149; Mahon FX, 2000, BLOOD, V96, P1070; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182-blood.V101.6.2368; Neumann E, 1870, ARCH HEILKUNDE; Nicolini FE, 2011, BLOOD, V118, P5697, DOI 10.1182-blood-2011-07-367326; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056-NEJMoa022457; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016-j.ccr.2009.09.028; Preudhomme C, 2010, NEW ENGL J MED, V363, P2511, DOI 10.1056-NEJMoa1004095; Puccetti E, 2000, CANCER RES, V60, P3409; Pye SM, 2008, BLOOD, V111, P5505, DOI 10.1182-blood-2007-10-114900; Quintas-Cardama A, 2010, SEMIN HEMATOL, V47, P371, DOI 10.1053-j.seminhematol.2010.06.004; Radich JP., 2007, HEMATOLOGY AM SOC HE, V1, P384; Ramirez P, 2008, ONCOLOGIST, V13, P424, DOI 10.1634-theoncologist.2007-0170; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038-243290a0; Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056-NEJMoa0912614; Savage D G, 1997, Curr Opin Hematol, V4, P369; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182-blood.V99.10.3530; Schultheis B, 2012, LEUKEMIA RES, V36, P271, DOI 10.1016-j.leukres.2011.09.025; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016-S1535-6108(02)00096-X; TALPAZ M, 1986, BRIT J HAEMATOL, V64, P87, DOI 10.1111-j.1365-2141.1986.tb07576.x; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182-blood.V99.6.1928; TALPAZ M, 1991, ANN INTERN MED, V114, P532; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056-NEJMoa055229; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016-S0140-6736(01)06535-7; Virchow R., 1845, FRORIEPS NOTIZEN, V36, P151
dc.description.citedCount 3
dc.description.citedTotWOSCount 4
dc.description.citedWOSCount 4
dc.format.extentCount 7
dc.identifier.coden PTBIA
dc.identifier.pubmedID 22743097
dc.identifier.scopusID 84864744865
dc.publisher.address 23 RUE LINOIS, 75724 PARIS, FRANCE
dc.relation.ispartOfISOAbbr Pathol. Biol.
dc.relation.ispartOfIssue 4
dc.relation.ispartofPubTitle Pathologie Biologie
dc.relation.ispartofPubTitleAbbr Pathol. Biol.
dc.relation.ispartOfVolume 60
dc.source.ID WOS:000310171400006
dc.type.publication Journal
dc.subject.otherAuthKeyword BCR-ABL
dc.subject.otherAuthKeyword Chronic myeloid leukemia
dc.subject.otherAuthKeyword Imatinib
dc.subject.otherAuthKeyword Targeted therapy
dc.subject.otherAuthKeyword Tyrosine kinase inhibitors
dc.subject.otherChemCAS imatinib, 152459-95-5, 220127-57-1
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS Fusion Proteins, bcr-abl
dc.subject.otherChemCAS Piperazines
dc.subject.otherChemCAS Protein Kinase Inhibitors
dc.subject.otherChemCAS Protein-Tyrosine Kinases,
dc.subject.otherChemCAS Pyrimidines
dc.subject.otherChemCAS imatinib, BKJ8M8G5HI
dc.subject.otherIndex imatinib
dc.subject.otherIndex article
dc.subject.otherIndex cancer chemotherapy
dc.subject.otherIndex chronic myeloid leukemia
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex health care system
dc.subject.otherIndex human
dc.subject.otherIndex malignant neoplastic disease
dc.subject.otherIndex medical research
dc.subject.otherIndex molecularly targeted therapy
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Drug Resistance, Neoplasm
dc.subject.otherIndex Fusion Proteins, bcr-abl
dc.subject.otherIndex Humans
dc.subject.otherIndex Leukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subject.otherIndex Molecular Targeted Therapy
dc.subject.otherIndex Piperazines
dc.subject.otherIndex Protein Kinase Inhibitors
dc.subject.otherIndex Protein-Tyrosine Kinases
dc.subject.otherIndex Pyrimidines
dc.subject.otherIndex Translocation, Genetic
dc.subject.otherKeywordPlus CHRONIC MYELOGENOUS LEUKEMIA
dc.subject.otherKeywordPlus CHRONIC MYELOCYTIC-LEUKEMIA
dc.subject.otherKeywordPlus TYROSINE KINASE-ACTIVITY
dc.subject.otherKeywordPlus LOW-DOSE CYTARABINE
dc.subject.otherKeywordPlus ABL-POSITIVE CELLS
dc.subject.otherKeywordPlus CHRONIC-PHASE
dc.subject.otherKeywordPlus INTERFERON-ALPHA
dc.subject.otherKeywordPlus PHILADELPHIA-CHROMOSOME
dc.subject.otherKeywordPlus CYTOGENETIC RESPONSES
dc.subject.otherKeywordPlus IMATINIB MESYLATE
dc.subject.otherWOS Pathology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account